Verici Dx to Launch TranscripTx™ Transplant Genetic Test in Q4 2026
Albeit still a relatively small business (£5.1m mrkcap), certainly punches above it weight.
Today announcing that in Q4'26, it plans to launch a new "1st-in-class" genetic RNA blood test TranscripTx.
This diagnostic is specifically designed for the transplant community and can identify key variations in a person’s genes that are known to impact biological processes relevant to transplant patients. Information that may accelerate new drug development, inform ongoing clinical trials and improve medical management protocols.
CEO Sara Barrington commenting: "This test underscores our commitment to pioneering personalised diagnostics in transplantation, maximising the strategic value of our clinical data while offering a vital new resource for therapeutic development and patient care."
Disclosure: Verici Dx is a Vox Markets client
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
